Loading stock data…
PLUS THERAPEUTICS, Inc. (PSTV)
$3.83+0.05 (+1.32%)
Market ClosedLast close Jul 24
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Plus Therapeutics, Inc. in the Healthcare sector is trading at $3.83 with a market capitalization of $38M. Wall Street consensus targets $36.00 (4 analysts), implying a +839.9% move over the next 12 months. The stock is currently near its 52-week low of $2.90, remaining 56.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +839.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.12M↓ | -$5.74M↓ | -$4.48M↓ | -$1.54M↑ | -$3.54M |
| Net Income | -$6.95M↓ | -$5.71M↓ | -$4.42M↓ | $5.15M↑ | -$17.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented r...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$37.86M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.26
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-99.75%
Volume
Today's trading volume
61,255
Recent News
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company focused on central nervous system (“CNS”) cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to CNSY, effective August 3, 2026. Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit.
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)
Company confirms name change and reaffirms 2026 objectivesPlus Therapeutics, Inc. (NASDAQ:PSTV), a healthcare company focused on central nervous system cancers, announced it will rebrand as Cerenome and begin trading on the Nasdaq under the new ticker symbol CNSY on August 3, 2026.
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending shares of the Nasdaq-listed company up 8.7% to $5.89 Thursday. CNSide Diagnostics'...
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching. Holders captured the move; new entrants face tougher math from here. The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss ... Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6